Abstract
BackgroundStudy results on the prognostic value of CD11b for acute myeloid leukemia (AML) patients are inconsistent. An up-to-date meta-analysis was conducted to assess the prognostic value of CD11b expression level for AML patients.MethodsElectronic databases including PubMed, Embase, Cochrane Library, Web of Science and Chinese BioMedical Literature Database (CBM) were searched to identify studies that investigated the association between CD11b expression level and prognosis of AML patients. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95% CI for complete remission rate (CRR) were calculated using Revman 5.3 and Stata 11.0.Results13 total studies with 2619 patients were included in this meta-analysis. Results of the meta-analysis showed that CD11b positivity was associated with lower CRR (OR = 0.44; 95% CI, 0.25–0.79; p = 0.006) and shorter OS (HR = 0.66; 95% CI, 0.55–0.80; p < 0.0001), but did not affect DFS (HR = 0.67; 95% CI, 0.31–1.48; p = 0.32). Subgroup analysis by ethnicity, cut-off value for CD11b positivity, treatment, subtype and sample preparation method showed no significant interaction between these factors with the prognostic value of CD11b expression level for AML patients. Sensitivity analysis yielded consistent results with the main meta-analysis.ConclusionCD11b positivity could predict a poor prognosis for AML patients. Thus, CD11b expression level might be considered a prognostic biomarker for AML patients.
Highlights
Acute myeloid leukemia (AML) is the most common type of leukemia that affects adults, with a prevalence of 3.8 cases per 10,000 adults rising to 17.9 cases per 10,000 adults aged 65 years and older [1]
Results of the metaanalysis showed that Cluster of differentiation 11b (CD11b) positivity was associated with lower complete remission rate (CRR) (OR = 0.44; 95% confidence intervals (CIs), 0.25–0.79; p = 0.006) and shorter overall survival (OS) (HR = 0.66; 95% CI, 0.55–0.80; p < 0.0001), but did not affect disease-free survival (DFS) (HR = 0.67; 95% CI, 0.31–1.48; p = 0.32)
Cut-off value for CD11b positivity, treatment, subtype and sample preparation method showed no significant interaction between these factors with the prognostic value of CD11b expression level for AML patients
Summary
Acute myeloid leukemia (AML) is the most common type of leukemia that affects adults, with a prevalence of 3.8 cases per 10,000 adults rising to 17.9 cases per 10,000 adults aged 65 years and older [1]. It is one protein subunit that forms the heterodimeric integrin alpha-M beta-2 molecule with cluster of differentiation 18 (CD18), named as macrophage-1 antigen or macrophage-1 antigen (Mac-1), complement receptor 3 (CR3)or MO1[11, 12,13] This protein can participate in cell activation, chemotaxis, cytotoxicity, phagocytosis and regulates interaction of leukemic cells with microenvironment through binding to its ligands, such as inactivated complement component 3b (iC3b), intercellular adhesion molecule (ICAM), fibrinogen, beta-glukanes, coagulation factor X etc.[14,15,16,17,18,19]. An up-to-date meta-analysis was conducted to assess the prognostic value of CD11b expression level for AML patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
